4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate | 717102-85-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
• CAS: 717102-85-7
• 化学式: C56H62F2N4O18
• 分子量: 1117.1
• InChiKey: CJCASBQEPSYJRX-XPOYNFBASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.45
• 重原子数：
  80
• 可旋转键数：
  16
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  330
• 氢给体数：
  7
• 氢受体数：
  20

文献信息

• Combination chemotherapy
  申请人：ANORMED INC.

  公开号：EP1530969A1

  公开（公告）日：2005-05-18

  The invention relates to a pharmaceutical composition, a therapeutic combination product and a kit comprising a sterically hindered platinum coordination compound and a non-platinum based anti-cancer agent and a pharmaceutically-acceptable carrier or diluent; to the use thereof for the manufacture of a medicament for inhibiting the growth of tumour cells in a human afflicted therewith; to a method of inhibiting the growth of tumour cells in a human afflicted therewith which comprises administering to such human an effective tumour cell growth inhibiting amount of such a therapeutic combination product or of a pharmaceutical composition of the invention; in particular when the sterically hindered platinum coordination compound is (SP-4-3)-(cis)-am-minedichloro-[2-methylpyridine]platinum (II), or a pro-drug thereof, and the non-platinum based anti-cancer agent is selected from Taxol Gemcitabine, Navelbine, Doxil, 5-FU and Taxotere.

  本发明涉及一种药物组合物、一种治疗组合产品和一种试剂盒，其中包括一种立体受阻的铂配位化合物和一种非铂类抗癌剂以及一种药学上可接受的载体或稀释剂；本发明还涉及用其制造一种药物，以抑制受其困扰的人体内肿瘤细胞的生长；一种抑制肿瘤细胞在患者体内生长的方法，该方法包括向患者施用有效的肿瘤细胞生长抑制量的本发明的治疗性复方产品或药物组合物；特别是当立体受阻的铂配位化合物是(SP-4-3)-(顺式)-氨基二氯-[2-甲基吡啶]铂(II)或其原药，而非铂类抗癌剂选自 Taxol Gemcitabine、Navelbine、Doxil、5-FU 和 Taxotere 时。
• Peptide-based methods for treating pancreatic cancer
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10016480B2

  公开（公告）日：2018-07-10

  Methods for treating a subject for pancreatic cancer via administration of small anti-inflammatory peptides are disclosed. The peptides may be administered in conjunction with another therapeutic agent, such as a chemotherapeutic agent, or therapeutic regimen. In some cases, the anti-inflammatory peptide that finds use in the subject methods has the amino acid sequence Lys-Phe-Arg-Lys-Ala-Phe-Lys-Arg-Phe-Phe (SEQ ID NO:1) or a multimer, derivative, or variant thereof.

  本研究公开了通过施用小型抗炎肽治疗胰腺癌的方法。这些肽可与另一种治疗剂（如化疗剂）或治疗方案联合使用。在某些情况下，本发明方法中使用的抗炎肽具有Lys-Phe-Arg-Lys-Ala-Phe-Lys-Arg-Phe-Phe（SEQ ID NO:1）的氨基酸序列或其多聚物、衍生物或变体。
• Imageable polymers
  申请人：Biocompatibles UK Ltd.

  公开号：US10556022B2

  公开（公告）日：2020-02-11

  This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system.

  本发明涉及可成像聚合物，特别是由聚乙烯醇组成的聚合物，并涉及其制造方法以及由聚合物组成的栓塞微球。这些微球可在栓塞过程中成像，并可装载药物或其他治疗剂，以提供可成像的给药系统。
• COMBINATION TREATMENT OP A G2 CHECKPOINT INHIBITOR (SB-218078) AND A CHEMOTHERAPEUTIC AGENT FOR TUMORIGENIC CELLS IN SOLID TUMORS
  申请人：Istituto Superiore di Sanità

  公开号：EP2445500A1

  公开（公告）日：2012-05-02
• EP3215184B1
  申请人：——

  公开号：EP3215184B1

  公开（公告）日：2021-03-03